Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases

Ali Kabir¹, Abdolreza Pazouki¹*, Motahareh Jafari¹, Somayye Mokhber¹, Mohammad Vaziri¹ and Seyed Moayed Alavian²

¹Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran; ²Middle East Liver Disease Center, Tehran, Iran

Received 7 May 2016; revised 20 June 2016; accepted 3 July 2016

ABSTRACT

Background: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases.

Methods: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran.

Results: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher percentage of hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012). Conclusion: The level of anti-HBs surface antigen antibody’s titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.

DOI: 10.18869/acadpub.ibj.21.3.197

Keyword: Hepatitis B vaccines, Obesity, Liver diseases, Immunosuppressive agent

INTRODUCTION

Iran is among countries with an intermediate prevalence of hepatitis B virus (HBV).[1] Vaccination is a very suitable strategy for preventing HBV infection.[2] A protective level of anti-hepatitis B (anti-HBs) is necessary to assure the preventive effect of vaccination.[2] However, cases with poor response to hepatitis B vaccine should be considered by using new vaccination strategies. To develop such new strategies, we should first determine the possible causes of insufficient response to vaccination. One of the probable non-responder groups to hepatitis B vaccine is the group of obese cases.

Based on the two systematic reviews, the prevalence of obesity is between 12.6% and 25.9%[3,4] in Iranian adult population, while in many countries, it is more than 50%.

Two previous studies on public safety personnel[5] or hospital staffs[6] have shown that higher body mass index (BMI) is a marker of poor response to hepatitis B vaccine. Two others have indicated that the gluteal injection of hepatitis B vaccine results in lower immunogenicity compare to deltoid injection, which is supposed to be related to the higher amount of fat tissue in gluteal region.[7,8]

In most previous studies that have evaluated the role of BMI as a risk factor for response to hepatitis B vaccine, their main goal was not assessing BMI as the main exposure. However, they aimed at evaluating the role of BMI beside many other risk factors (like cross-sectional studies) and not as a main factor (like case-control or cohort studies). Furthermore, they just examined multiple factors such as age, sex, BMI, and comorbidities.[5,6] Here, we have designed a control group with normal BMI to compare with obese and overweight cases. Considering the prevalence of HBV and the increasing trend of obesity in Iran, the present
study was designed to compare the vaccine efficacy in obese/overweight and non-obese cases.

MATERIALS AND METHODS

In this cross-sectional study, 242 obese and 85 non-obese individuals were participated between March 2013 and March 2014. Some cases were selected from a referral clinic for obesity, and some other cases as well as all controls were chosen from a referral hepatology clinic, both in Tehran, Iran.

Cases were individuals with BMI equal to or higher than 25 and controls with BMI lower than 25 kg/m², respectively. Controls were selected from referral cases with non-alcoholic fatty liver disease, auto-immune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. The controls were free of viral hepatitis B or C and HIV. In other words, any liver diseases that did not have any effect on the presence or the level of HBsAb were considered as control cases.

Demographic data of both cases and controls were obtained from the profile of both groups that included age, gender, education, vaccination history, comorbidities, immunosuppressive medication, liver disease in participants or their families, height, weight, BMI, and HBV profile (consist of anti-HBs titer) Anti-HBs titer equal to or higher than 10 mIU/mL was considered positive.

We estimated the sample size of 242 in cases and 88 in controls based on two-sample comparison of means formula, considering type I and II errors, mean and standard deviation of anti-HBs titer in the case and control groups and the ratios of the case group to the control were equal to 0.05, 0.1, 160, 110, 120, 60, and 2.75, respectively. However, we did not find more than 85 controls.

Ethics

The study was approved by the ethics committee of Iran University of Medical Sciences, Iran, Tehran. The study protocol was also conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution’s human research committee. An informed consent was obtained from all participants for using their data in research projects anonymously.

Statistical analysis

Data analysis was performed based on mean±standard deviation (SD), median±interquartile range (IQR), percentage, odds ratio (OR) with 95% confidence interval (95% CI), chi-square, Mann-Whitney U, Kruskal Wallis H, Median test, Spearman’s rho correlation coefficient, logistic (Forward-Wald model), and linear regression (stepwise model) using SPSS 20.0 (SPSS Inc., Chicago, Illinois, USA). P value less than 0.05 was considered statistically significant. In regression analysis, all variables with P<0.2 were entered in the model if they had confounder role in the relation between the level of anti-HBs titer and BMI category (≥25 or <25 kg/m²).

RESULTS

The mean±SD age of the participants was 42±12.9 years, and 202 out of 327 cases (61.8%) were female. We observed that 83 obese cases (43.7%) responded to vaccination, without any significant difference, versus 15 (34.9%) non-obese ones. None of the factors, including sex, age, height, immunosuppressive medication usage, family history of liver diseases, type of liver diseases, SGOT, SGPT, and alkaline phosphatase were associated with response to vaccination. Cases with the presence of liver disease had significantly higher response to vaccination (OR: 3, 95% CI: 1.4, 6.6; P=0.004). Mean weight (93.4±26 vs. 113.2±31.1 kg, P<0.001) and BMI (33.8±8.8 vs. 41.1±10 kg/m², P<0.001) were lower in cases with response to vaccination. The comparison between BMI and the presence of liver disease indicated that only BMI (adjusted OR: 0.92, 95% CI: 0.88, 0.96; P<0.001) had significant association with response to vaccination. Higher BMI caused a lower response rate as OR was significantly lower than 1.

Mean (P=0.011) but not the median of the level of anti-HBs titer decreased significantly by an increase in BMI. Means (SD) of BMI categories, including 18-24.9, 25-29.9, 30-34.9, and ≥35 kg/m² were equal to 279.4 (393.7), 241.9 (337.3), 195.2 (271.6), and 70.0 (164.4) mIU/mL, respectively. The sex and family history of liver disease were not different between the obese group and the controls. The non-obese group had significantly higher immunosuppressive medication usage (P<0.001) and liver diseases (P<0.001) but lower age (P=0.046) (Table 1). The type of liver disease was mostly non-alcoholic fatty liver disease in cases, while autoimmune hepatitis in controls (P<0.001). The pattern of vaccination was also different between the two groups (P<0.001). Among individuals with the specified history of vaccination, 146 (74.9%) of obese group and 21 (51.2%) of non-obese one had vaccination against hepatitis B (Table 1). In brief, cases and controls were significantly different in view of immunosuppressive medication usage, liver diseases, age, type of liver disease, and pattern of vaccination. Therefore, association between these probable confounders and anti-HBs titer was evaluated in the next step. Titer of anti-HBs was
Kabir et al. Anti-Hepatitis B Antibody and Obesity

Iran. Biomed. J. 21 (3): 197-202

...

... male. BMI≤25 kg/m²[9], older age (more than 39)[5,10,11], smoking[5,10], obesity[5,10-12], and type P-

... in this model, only quantitative BMI remained as confounder variables in evaluating factor for poor response to hepatitis B vaccination. Its effect on anti-HBs titer can even be higher from the impact that acquired in our study because of unsuitable situation of our controls in response to hepatitis B vaccination.

In Iran, most hepatitis B vaccines are from Cuba. A Cuban hepatitis B vaccine on 64 nurse’s aid students caused a protective level of anti-HBs in 42.2% (http://ebnesina.ajaums.ac.ir/browse.php?a_id=46&sid =1&sl_lang=en), and in 235 health care providers was 81.2%. It was also 92.3% in our control group when their mean age was 39 years and most of them were female. BMI≤25 kg/m²[19], older age (more than 39)[5,10,11], smoking[5,10], obesity[5,10-12], male

| Characteristics | Cases (n=242) | Controls (n=85) |
|-----------------|--------------|----------------|
| Age, year, mean±SD | 42.9±12.1 | 39.4±14.7 |
| Female, no. (%) | 149 (61.6) | 53 (62.4) |
| Liver disease, no. (%) | 162 (66.9) | 85 (100) |
| Type of liver disease, no. (%) | | |
| NAFLD | 118 (73.3) | 22 (25.9) |
| Autoimmune hepatitis | 33 (20.5) | 47 (55.3) |
| PBC/PSC | 10 (6.2) | 16 (18.8) |
| Family history of liver disease, no. (%) | 29 (12.2) | 4 (4.7) |
| Vaccination history, no. (%) | | |
| No | 49 (20.2) | 20 (23.5) |
| One time | 9 (3.7) | 1 (1.2) |
| Two times | 11 (4.5) | 0 |
| Three times | 126 (52.1) | 20 (23.5) |
| Unknown | 47 (19.4) | 44 (51.8) |
| Immunosuppressive medication, no. (%) | 25 (10.3) | 34 (40) |

NAFLD, non-alcoholic fatty liver disease; no., number; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SD, standard deviation

| Characteristics | Cases (n=242) | Controls (n=85) |
|-----------------|--------------|----------------|
| Age, year, mean±SD | 42.9±12.1 | 39.4±14.7 |
| Female, no. (%) | 149 (61.6) | 53 (62.4) |
| Liver disease, no. (%) | 162 (66.9) | 85 (100) |
| Type of liver disease, no. (%) | | |
| NAFLD | 118 (73.3) | 22 (25.9) |
| Autoimmune hepatitis | 33 (20.5) | 47 (55.3) |
| PBC/PSC | 10 (6.2) | 16 (18.8) |
| Family history of liver disease, no. (%) | 29 (12.2) | 4 (4.7) |
| Vaccination history, no. (%) | | |
| No | 49 (20.2) | 20 (23.5) |
| One time | 9 (3.7) | 1 (1.2) |
| Two times | 11 (4.5) | 0 |
| Three times | 126 (52.1) | 20 (23.5) |
| Unknown | 47 (19.4) | 44 (51.8) |
| Immunosuppressive medication, no. (%) | 25 (10.3) | 34 (40) |

NAFLD, non-alcoholic fatty liver disease; no., number; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SD, standard deviation

significantly higher in patients with liver diseases and higher numbers of vaccination times but it was not related to sex, taking immunosuppressive medications, family history of liver disease, and type of liver disease (Table 2). Age was not correlated with the level of anti-HBs titer (P=0.581). Median±IQR of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6 mIU/mL, P=0.012). BMI had a reverse moderate correlation with the level of anti-HBs titer (r=-0.379, P<0.001).

In the present study, confounder variables in association between anti-HBs titer and BMI group (obese vs. non-obese) are liver diseases and the pattern of vaccination. Therefore, to adjust the effect of these confounder variables, we entered all confounders in addition to BMI category in a linear regression model. Among all related variables with significant or borderline association with anti-HBs titer, only the presence of liver disease (P=0.003) was an independent predictor of determining the level of anti-HBs titer (standardized beta=0.264). With the substitution of quantitative BMI instead of categorical BMI in this model, only quantitative BMI remained as the independent predictor of the level of anti-HBs titer (standardized beta=-0.292, P=0.001).

DISCUSSION

Control group (with normal BMI) used more immunosuppressive medications, had more percentage of liver diseases, were younger, had more percentage of autoimmune liver disease, and poorer vaccination history. Among these variables, only the presence of liver diseases and the higher numbers of vaccination times were correlated with the higher titer of anti-HBs. BMI had also a reverse moderate correlation with the level of anti-HBs titer. Therefore, the liver disease and the pattern of vaccination were considered as confounders in evaluating the association between BMI and anti-HBs titer. By adjustment of these variables, the presence of liver disease and lower BMI remained as independent predictors of anti-HBs titer in two separate models. This observation shows that obese individuals have significantly lower response to hepatitis B vaccination. We should, therefore, consider some strategies to overcome such weak response by increasing the subgroup of population.

Despite the unsuitable situation of controls in view of immunosuppression medication usage, liver disease, and vaccination history, they had a higher level of anti-HBs titers, showing that BMI is a significant major risk factor for poor response to hepatitis B vaccination. Its effect on anti-HBs titer can even be higher from the impact that acquired in our study because of unsuitable situation of our controls in response to hepatitis B vaccination.

In Iran, most hepatitis B vaccines are from Cuba. A Cuban hepatitis B vaccine on 64 nurse’s aid students caused a protective level of anti-HBs in 42.2% (http://ebnesina.ajaums.ac.ir/browse.php?a_id=46&sid =1&sl_lang=en), and in 235 health care providers was 81.2%. It was also 92.3% in our control group when their mean age was 39 years and most of them were female. BMI≤25 kg/m²[19], older age (more than 39)[5,10,11], smoking[5,10], obesity[5,10-12], male
Family history of liver disease was not associated with response to hepatitis B vaccine. However, one study has shown low response rate to hepatitis B vaccine in immunosuppressed patients with inflammatory bowel disease\textsuperscript{[14]}. Other investigations have revealed that immunosuppressive regimens used by mothers do not affect the offsprings' immune status\textsuperscript{[15]}. In our study, immunosuppressive treatment was not a significant variable for response to hepatitis B vaccine. However, the subject is controversial and needs more sophisticated studies.

A very recent meta-analysis showed that a significantly decreased response to hepatitis B vaccine is associated with age ≥40 years, male adults, BMI≥25 kg/m\textsuperscript{2}, being smoker, and adults with concomitant diseases\textsuperscript{[16]}. Poor vascularity of fat tissue and subsequent slow mobilization and processing of antigen, longer reaching time to the circulation from fat tissue, denaturizing antigens in fat tissue, poorer drainage of adipose tissue in comparison with muscle due to lower blood supply and subsequent higher adverse effects in subcutaneous vaccination are all mentioned as mechanisms of weak response to hepatitis B vaccination and higher side effects in subcutaneous in comparison with intramuscular

\begin{table}[h]
\centering
\caption{Anti-hepatitis B titer level in different subgroups}
\begin{tabular}{llc}
\hline
Characteristic & Anti-HBs level, mIU/mL, median±IQR & \textit{P} value \\
\hline
Sex & & \\
Male & 54±273.5 & 0.983 \\
Female & 49±174 & \\
Immunosuppressive usage & & \\
Yes & 100±968 & 0.232 \\
No & 48.5±185.5 & \\
Liver disease & & \\
Yes & 86±298.7 & 0.023 \\
No & 22±92 & \\
Type of liver disease & & \\
NAFLD & 86±271.5 & 0.258 \\
Autoimmune hepatitis & 100±4968 & \\
PBC/PSC & 45±22 & \\
Family history of liver disease & & \\
Yes & 96±548.8 & 0.799 \\
No & 50±161 & \\
Vaccination history & & \\
No & 39±328.4 & \\
One time & 5.5±32.8 & \\
Two times & 2±9 & 0.035 \\
Three times & 64.5±223.2 & \\
Unknown & 49.5±92 & \\
\hline
\end{tabular}
\end{table}

HBs, hepatitis B surface; IQR, inter-quartile range; mIU, mili international unit; mL, millilitter; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
The injection of hepatitis B vaccine with usual syringe in morbid obesity cases may be equal to subcutaneous injection, which has been shown to produce lower seroconversion rate and even rapid decline of antibody response than intramuscular injection\(^{[19]}\). A published study in JAMA showed that women have greater deltoid skin-fold thickness than men and need longer syringe. Women with weight less than 60 kg, 60-90 kg, and more than 90 kg needed 16-, 25-, and 38-mm needle to ensure intramuscular administration, respectively\(^{[19]}\). Because of some degrees of immunodeficiency in obese cases, booster immunizations might be helpful in these cases\(^{[20]}\). General recommendation now available for needle length has shown that needle should be long enough to reach the muscle mass for intramuscular vaccines, which causes both less local complications and maybe higher immunization\(^{[21]}\).

We have not checked the data of last vaccination, while it is known that anti-HBs are declined with time and may even become undetectable after several years. However, it remains for at least five and eight years in adults and children, respectively.\(^{[22]}\) Cross-sectional nature of the study, and unawareness from BMI at the time of vaccination are among other shortcomings of the present study.

Many debates have been issued about the obesity and hepatitis B vaccine. Most investigations, as mentioned earlier, did not design their studies according to different BMI and have just evaluated BMI beside other probable risk factors and demographic and anthropometric variables.\(^{[5,6]}\) However, our study has compared cases with different BMI in view of response to hepatitis B vaccination as its main goal. The control group in this study was selected from a referral center of hepatology clinic. Similar to our cases group (obese persons), the probability of both liver diseases and immunodeficiency is higher than general population. Therefore, such control group is superior to healthy, neighborhood, family members, or hospital controls because selected control group is more comparable with our cases.

The level of anti-HBs titer in obese cases is lower than the controls, even in the presence of important factors like male gender and older age as confounders. However, the presence of liver disease can be an important factor that significantly affects this relation. Hence, anti-HBs titer level in obese cases without liver disease is lower than non-obese cases without liver disease, and we therefore should use a suitable strategy to overcome this problem; For example, using longer needles for vaccination in these cases.

**ACKNOWLEDGMENTS**

This study was performed as a thesis by Motahareh Jafari under the supervision of Dr. Mohammad Vaziri and consultation of Dr. Ali Kabir in Faculty of Medicine of Iran University of Medical Sciences, Tehran, Iran. This study was funded and supported by Iran University of Medical Sciences, Tehran, Iran (Grant no. 90-04-140-16283).

**CONFLICTS OF INTEREST:** None declared.

**REFERENCES**

1. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. *Hepatitis monthly* 2008; 8(4): 281-294.
2. Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leopardi S. Hepatitis B vaccine by intradermal route in non responder patients: an update. *The world journal of gastroenterology* 2014; 20(30): 10383-10394.
3. Mirzazadeh A, Sadeghirad B, Haghdooest AA, Bahreini F, Kermaji MR. The prevalence of obesity in Iran in recent decade; a systematic review and meta-analysis study. *The iranian journal of public health* 2009; 38(3): 1-11.
4. Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larjiani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran; a systematic review. *The journal of diabetes and metabolic disorders* 2014; 13(1): 121.
5. Roome AJ, Walsh SJ, Carter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. *The journal of the american medical association* 1993; 270(24): 2931-2934.
6. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. *The journal of the american medical association* 1985; 254(22): 3187-3189.
7. Shaw FE Jr., Guess HA, Roets JM, Mohr FE, Coleman P, Mandel EZ, Roehm RR Jr., Talley WS, Hadler SC. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. *Vaccine* 1989; 7(5): 425-430.
8. Ukena T, Esber H, Bessette R, Parks T, Crocker B, Shaw FE, Jr. Site of injection and response to hepatitis
B vaccine. *The new england journal of medicine* 1985; 313(9): 579-580.

9. Estevez ZC, Betancourt AA, Muzio Gonzalez V, Baile NF, Silva CV, Bernal FH, Arias EP, Delhanty Fernandez A, Olazabal NM, del Rio Martin A, Batista LL, Veliz Rios G, Hernandez HH, Hernandez AB, Lugo EP, de la Torre Cruz J, Batista Marchec BL, Falcon LA, Brito JT, Leon DO, Saura PL. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. *Biologicals* 2007; 35(2): 115-122.

10. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. *American journal of preventive medicine* 1998; 15(1): 1-8.

11. Chlibek R, Smetana J, Sindelar R, Cecetkova B, Prymula R, Kohl I. Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age-impact of risk factors. *Epidemiologie, mikrobiologie, imunologie : casopis spolecnosti pro epidemiologii a mikrobiologii ceske lekarske spolecnosti je purkyne* 2007; 56(3): 119-128.

12. Young KM, Gray CM, Bekker LG. Is obesity a risk factor for vaccine non-responsiveness? *PloS one* 2013; 8(12): e82779.

13. Kabir A, Keshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. *Human vaccines* 2008; 4(5): 379-383.

14. Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. *World journal of gastroenterology* 2013; 19(9): 1349-1353.

15. Biggioggero M, Borghi MO, Gerosa M, Trespidi L, Cimaz R, Meroni PL. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. *Lupus* 2007; 16(8): 651-656.

16. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, Xu K, Ren J, Yao J, Li Y, Cao Q, Chen P, Xie T, Wang C, Wang B, Mao C, Ruan B, Jiang T, Li L. Factors influencing immunologic response to hepatitis B vaccine in adults. *Scientific reports* 2016; 6: 27251.

17. Zuckerman JN. The importance of injecting vaccines into muscle. Different patients need different needle sizes. *BMJ* 2000; 321(7271): 1237-1238.

18. Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. *BMJ* 2006; 333(7568): 571.

19. Poland GA, Borrud A, Jacobson RM, McDermott K, Wollan PC, Brakke D, Charboneau JW. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. *The journal of the american medical association* 1997; 277(21): 1709-1711.

20. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. *The lancet* 2000; 355(9203): 561-565.

21. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and mortality weekly report recommendations and reports* 2006; 55(RR-15): 1-48.

22. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy* 1998; 10(2): 137-158.